Telomir Pharmaceuticals, Inc.
For the period ended Sep 30, 2026. Filed Nov 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 6, 2026
TELO$0.57-17.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| Nine Months Ended September 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(3,417,700) | $(8,352,012) |
| Adjustments to reconcile net loss to net cash used in operations | ||
| Stock-based compensation expense | 303,881 | 5,298,278 |
| Stock-based compensation expense – stock option modification | 598,737 | — |
| Issuance of common stock for services | — | 840,000 |
| Change in operating assets and liabilities: | ||
| Prepaid expenses | (70,950) | (14,946) |
| Trade accounts payable and accrued liabilities | (368,779) | (258,161) |
| Accrued compensation - officer | (417,470) | — |
| Net cash used in operating activities | (3,372,281) | (2,486,841) |
| Cash flows from financing activities: | ||
| Repayment to officer | (155,518) | — |
| Proceeds from issuance of insurance loan payable | 224,789 | — |
| Repayments on insurance loan payable | (156,033) | — |
| Proceeds from TELI contribution, related party | 1,000,000 | — |
| Repayment of payable to related parties | (318,234) | — |
| Net proceeds from sale of common stock in ATM | 6,311 | — |
| Proceeds from sale of common stock | — | 5,550,008 |
| Proceeds from sale of common stock, related party | — | 3,000,000 |
| Net cash provided by financing activities | 601,315 | 8,550,008 |
| Net change in cash | (2,770,966) | 6,063,167 |
| Cash and cash equivalents, beginning of period | 7,286,670 | 1,266,131 |
| Cash and cash equivalents, end of period | $4,515,704 | $7,329,298 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $6,191 | $— |
| Cash paid for income tax | $— | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.